<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044223</url>
  </required_header>
  <id_info>
    <org_study_id>PSA_Sepsis_M_1_2</org_study_id>
    <nct_id>NCT03044223</nct_id>
  </id_info>
  <brief_title>Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis</brief_title>
  <acronym>MIPSA</acronym>
  <official_title>Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study focuses on patients with Pseudomonas aeruginosa (PSA) sepsis. The aim of
      the present study is to find out whether the M1 (pro-inflammatory) or M2 (anti-inflammatory)
      phenotype predominates in blood monocytes in critically ill patients with PSA-sepsis, and
      whether the severity of sepsis and outcome is associated with distinct monocyte phenotype and
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During bacterial related sepsis, one of the key playing cells are macrophages, monocytes and
      T-lymphocytes (Hotchkiss et al., 2003). Macrophages and monocytes are supposed to be
      essential for the septic reaction to Gram-negative bacteria (Hotchkiss et al. 2003).
      Generally, there are two dominant types of macrophages: the pro-inflammatory M1 macrophage
      and the anti-inflammatory M2 macrophage (Mantovani et al., 2006). Similar to this macrophage
      characteristics, monocytes can also be categorized into pro-or anti-inflammatory. These
      macrophage/monocyte phenotypes can be differentiated in vitro from freshly isolated human
      blood monocytes using either GM-CSF giving raise to M1 macrophage/monocyte or M-CSF resulting
      in M2 macrophage/monocyte (Mantovani et al., 2006; Neu et al., 2013). Brunialti et al. (2012)
      have already demonstrated that the population of antiinflammatory M2 monocytes in septic
      patients is bigger than the pro-inflammatory M1 population. However, the authors did not
      further analyze the underlying mechanisms of M2 polarization nor did they identify the
      sepsis-causing pathogens.

      In the present study, monocytes and macrophages of patients with Pseudomonas aeruginosa (PSA)
      sepsis are characterized by their surface marker expression profile via flow cytometry and
      cytokine pattern by ELISA in vivo and after ex-vivo LPS stimulation. In addition, an ex-vivo
      model system for PSA induced sepsis is validated. Blood of critically ill patients in the ICU
      infected with PSA is sampled to isolate peripheral blood mononuclear cells (PBMCs). Blood
      monocytes are analyzed for surface marker expression to determine the relative proportions of
      M1 and M2 monocytes in these patients and in healthy controls by flow cytometry
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Monocyte surface marker expression in critically ill patients with Pseudomonas aeruginosa sepsis</measure>
    <time_frame>two years</time_frame>
    <description>Monocyte type 1, type 2 surface marker expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine concentrations in serum and production after ex-vivo stimulation of isolated monocytes of critically ill patients with Pseudomonas aeruginosa sepsis with LPS</measure>
    <time_frame>four years</time_frame>
    <description>IL-8 and IFN-gamma</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pseudomonas Infections</condition>
  <condition>Pseudomonas Septicemia</condition>
  <condition>Pseudomonas; Pneumonia</condition>
  <condition>Pseudomonal Bacteraemia</condition>
  <condition>Pseudomonas Urinary Tract Infection</condition>
  <condition>Pseudomonas Gastrointestinal Tract Infection</condition>
  <condition>Sepsis</condition>
  <condition>Sepsis, Severe</condition>
  <condition>Critically Ill</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients with sepsis with microbiologically proven infection with
        Pseudomonas aeruginosa
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  critically ill patients with sepsis

          -  microbiologically proven infection with Pseudomonas aeruginosa

        Exclusion Criteria:

          -  life expectancy &lt; 24 hours

          -  participation in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Weiss, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ulm, University Hospital Ulm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Sedlag, Biochemist</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Ulm, Institute of Microbiology and Biotechnology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manfred Weiss, MD, MBA</last_name>
    <phone>+49 731 500 60226</phone>
    <email>manfred.weiss@uniklinik-ulm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eberhard Barth, MD</last_name>
    <phone>+49 731 500 60050</phone>
    <email>eberhard.barth@uniklinik-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic of Anesthesiology</name>
      <address>
        <city>Ulm</city>
        <zip>89070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Weiss, MD, MBA</last_name>
      <phone>+49-(0)731-500-60226</phone>
      <email>manfred.weiss@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Eberhard Barth, MD</last_name>
      <phone>+49-(0)731-500-60050</phone>
      <email>eberhard.barth@uniklinik-ulm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Eberhard Barth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Goergieff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendrik Bracht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Gebhard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doris Henne-Bruns, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc-Eric Halatsch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl-Heinz Orend, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Essig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Riedel, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Sedlag, Biochemist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Brunialti MK, Santos MC, Rigato O, Machado FR, Silva E, Salomao R. Increased percentages of T helper cells producing IL-17 and monocytes expressing markers of alternative activation in patients with sepsis. PLoS One. 2012;7(5):e37393. doi: 10.1371/journal.pone.0037393. Epub 2012 May 31.</citation>
    <PMID>22693573</PMID>
  </reference>
  <reference>
    <citation>Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003 Jan 9;348(2):138-50. Review.</citation>
    <PMID>12519925</PMID>
  </reference>
  <reference>
    <citation>Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol. 2007 Jan;37(1):14-6. Review.</citation>
    <PMID>17183610</PMID>
  </reference>
  <results_reference>
    <citation>Neu C, Sedlag A, Bayer C, FÃ¶rster S, Crauwels P, Niess JH, van Zandbergen G, Frascaroli G, Riedel CU. CD14-dependent monocyte isolation enhances phagocytosis of listeria monocytogenes by proinflammatory, GM-CSF-derived macrophages. PLoS One. 2013 Jun 11;8(6):e66898. doi: 10.1371/journal.pone.0066898. Print 2013.</citation>
    <PMID>23776701</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Manfred Weiss</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>pseudomonas aeruginosa</keyword>
  <keyword>critically ill patient</keyword>
  <keyword>sepsis</keyword>
  <keyword>monocyte</keyword>
  <keyword>macrophage</keyword>
  <keyword>cytokine</keyword>
  <keyword>severity of disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

